@article {Chan:January 2001:0953-0673:19,
	author = "Chan, F. K. L.",
	author = "Sung, J. J. Y.",
	author = "Ching, J. Y. L.",
	author = "Wu, J. C. Y.",
	author = "Lee, Y. T.",
	author = "Leung, W. K.",
	author = "Hui, Y.",
	author = "Chan, L. Y.",
	author = "Lai, A. C. W.",
	author = "Chung, S. C. S.",
	title = "Randomized trial of low-dose misoprostol and naproxen vs. nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs",
	journal = "Alimentary Pharmacology & Therapeutics",
	volume = "15",
	year = "January 2001",
	abstract = "Background:&#8194; <P></P>Prophylactic misoprostol or non-steroidal anti-inflammatory drugs (NSAIDs) with low gastric toxicity (nabumetone) has been shown to reduce mucosal injury. Aim:&#8194; <P></P>To compare nabumetone vs. co-therapy of naproxen with low-dose misoprostol for secondary prevention of upper gastrointestinal bleeding in NSAID users. Methods:&#8194; <P></P>NSAID users presenting with upper gastrointestinal bleeding were enrolled if they required long-term NSAIDs. After ulcer healing, they were randomized to receive: naproxen (500-1000&#8201;mg/day) and misoprostol (200&#8201;&#956;g b.d.), or nabumetone (1000-1500&#8201;mg/day) and placebo misoprostol for 24&#8201;weeks. The primary end-point was recurrent upper gastrointestinal bleeding. The secondary end-point was the proportion of patients suffering from major gastrointestinal events including ulcer bleeding, symptomatic ulcers and severe dyspepsia. Results:&#8194; <P></P>A total of 90 patients were included in the intention-to-treat analysis (misoprostol/naproxen 45, nabumetone 45). Recurrent bleeding occurred in 10 patients (22.2%) receiving misoprostol/naproxen compared with three (6.7%) receiving nabumetone (relative risk 3.33, 95% CI: 0.98-11.32, <I>P</I>&#61;0.069). The proportion of patients suffering from major gastrointestinal events at 24&#8201;weeks was 31.1% in the misoprostol/naproxen group and 28.9% in the nabumetone group. Conclusions:&#8194; <P></P>Misoprostol/naproxen is not superior to nabumetone for secondary prevention of upper gastrointestinal bleeding. Neither low-dose misoprostol nor nabumetone is adequate for high-risk NSAID users.",
	pages = "19-24(6)",
	url = "http://www.ingentaconnect.com/content/bsc/apt/2001/00000015/00000001/art00003"
}